Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
The DEL-1/β3 integrin axis promotes regulatory T cell responses during inflammation resolution
Xiaofei Li, … , Veronica De Rosa, George Hajishengallis
Xiaofei Li, … , Veronica De Rosa, George Hajishengallis
Published August 20, 2020
Citation Information: J Clin Invest. 2020;130(12):6261-6277. https://doi.org/10.1172/JCI137530.
View: Text | PDF
Research Article Autoimmunity Inflammation

The DEL-1/β3 integrin axis promotes regulatory T cell responses during inflammation resolution

  • Text
  • PDF
Abstract

FOXP3+CD4+ regulatory T cells (Tregs) are critical for immune homeostasis and respond to local tissue cues, which control their stability and function. We explored here whether developmental endothelial locus-1 (DEL-1), which, like Tregs, increases during resolution of inflammation, promotes Treg responses. DEL-1 enhanced Treg numbers and function at barrier sites (oral and lung mucosa). The underlying mechanism was dissected using mice lacking DEL-1 or expressing a point mutant thereof, or mice with T cell–specific deletion of the transcription factor RUNX1, identified by RNA sequencing analysis of the DEL-1–induced Treg transcriptome. Specifically, through interaction with αvβ3 integrin, DEL-1 promoted induction of RUNX1-dependent FOXP3 expression and conferred stability of FOXP3 expression upon Treg restimulation in the absence of exogenous TGF-β1. Consistently, DEL-1 enhanced the demethylation of the Treg-specific demethylated region (TSDR) in the mouse Foxp3 gene and the suppressive function of sorted induced Tregs. Similarly, DEL-1 increased RUNX1 and FOXP3 expression in human conventional T cells, promoting their conversion into induced Tregs with increased TSDR demethylation, enhanced stability, and suppressive activity. We thus uncovered a DEL-1/αvβ3/RUNX1 axis that promotes Treg responses at barrier sites and offers therapeutic options for modulating inflammatory/autoimmune disorders.

Authors

Xiaofei Li, Alessandra Colamatteo, Lydia Kalafati, Tetsuhiro Kajikawa, Hui Wang, Jong-Hyung Lim, Khalil Bdeir, Kyoung-Jin Chung, Xiang Yu, Clorinda Fusco, Antonio Porcellini, Salvatore De Simone, Giuseppe Matarese, Triantafyllos Chavakis, Veronica De Rosa, George Hajishengallis

×

Figure 7

RUNX1 is required for the ability of DEL-1 to induce Treg differentiation.

Options: View larger image (or click on image) Download as PowerPoint
RUNX1 is required for the ability of DEL-1 to induce Treg differentiatio...
(A and B) Naive splenic CD4+ cells from WT mice were differentiated into Tregs in the presence of DEL-1–Fc or Fc control for 3 days. RNA-seq analysis of the Treg transcriptome is presented as expression in the DEL-1–Fc group relative to the Fc control (log2 values) (n = 3 biological repeats/group). (A) MA (left) and volcano (right) plots show the distribution of gene expression. (B) Heatmaps show the significantly regulated genes (FDR < 0.05) annotated with ontology terms (Gene Ontology [GO] and PANTHER protein class). (C) Relative mRNA expression of Runx1, Runx3, and Cbfb in Tregs in in vitro culture on day 3 by qPCR (n = 6 replicates; 2 separate cell isolations). (D) MFI of RUNX1 in RUNX1+FOXP3+ iTregs (n = 6 replicates; 2 separate cell isolations). (E and F) Naive splenic CD4+ cells from CD4-Cre+ Runx1fl/fl mice or CD4-Cre– Runx1fl/fl littermate controls were differentiated, or not, into Tregs in the presence of Fc control or DEL-1–Fc for 4 days. (E) FACS plots and (F) percentage of FOXP3+ cells in CD4+ T cells from the in vitro culture system on day 4 (n = 6 replicates; 2 separate cell isolations). (G–L) Groups of littermate Del1WT CD4-Cre+ Runx1fl/fl and Del1KO CD4-Cre+ Runx1fl/fl mice were subjected to ligature-induced periodontitis for 10 days and ligatures were removed on day 10 for 5 days. FACS plots of Tregs (top) and Th17 cells (bottom) in gingival tissues (G) and cLNs (J) and percentages and absolute numbers of Tregs (H and K) and Th17 cells as well as Treg/Th17 cell ratio (I and L) in gingival tissues (H and I) and cLNs (K and L) of littermate Del1WT CD4-Cre+ Runx1fl/fl and Del1KO CD4-Cre+ Runx1fl/fl mice on day 15 (n = 6 mice/group). Data are means ± SD and are pooled from 2 independent experiments. ****P < 0.0001 by 1-way ANOVA with Dunnett’s post hoc test for comparison with Fc control (C) or 2-tailed Student’s t test (D, F, H, I, K, and L). NS, not significant.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts